Headquarters: Cambridge, Massachusetts, USA Founded: 2018 Focus: Prion diseases, neurodegenerative disorders, anti-prion therapeutics Website: [prionab.com](https://www.prionab.com)
Prionab is a biotechnology company dedicated to developing disease-modifying therapies for prion diseases and related neurodegenerative disorders. The company targets the pathological misfolding of the prion protein (PrP<sup>Sc</sup>), which is the causative agent of fatal transmissible spongiform encephalopathies (TSEs)[@prusiner2024].
Based in the biotechnology hub of Cambridge, Massachusetts, Prionab leverages cutting-edge research in protein misfolding, molecular chaperones, and immunotherapeutic approaches to address these invariably fatal neurological conditions. The company's mission is to transform prion diseases from universally fatal diagnoses into manageable, treatable conditions.
Prionab was founded in 2018 by a team of neuroscientists and protein biochemists who recognized the urgent unmet need for effective prion disease therapeutics. The founding team brought together decades of combined experience in prion biology, drug discovery, and clinical neurology.
Headquarters: Cambridge, Massachusetts, USA Founded: 2018 Focus: Prion diseases, neurodegenerative disorders, anti-prion therapeutics Website: [prionab.com](https://www.prionab.com)
Prionab is a biotechnology company dedicated to developing disease-modifying therapies for prion diseases and related neurodegenerative disorders. The company targets the pathological misfolding of the prion protein (PrP<sup>Sc</sup>), which is the causative agent of fatal transmissible spongiform encephalopathies (TSEs)[@prusiner2024].
Based in the biotechnology hub of Cambridge, Massachusetts, Prionab leverages cutting-edge research in protein misfolding, molecular chaperones, and immunotherapeutic approaches to address these invariably fatal neurological conditions. The company's mission is to transform prion diseases from universally fatal diagnoses into manageable, treatable conditions.
Prionab was founded in 2018 by a team of neuroscientists and protein biochemists who recognized the urgent unmet need for effective prion disease therapeutics. The founding team brought together decades of combined experience in prion biology, drug discovery, and clinical neurology.
Cambridge, Massachusetts, provides Prionab with access to world-class research institutions including MIT, Harvard, and leading hospitals such as Massachusetts General Hospital and Brigham and Women's Hospital. This ecosystem has facilitated collaborations with academic researchers and access to cutting-edge technologies for studying protein misfolding diseases.
The company has operated as a privately held biotechnology firm, receiving funding through a combination of private investment, NIH grants focused on rare disease research, and strategic partnerships with academic institutions specializing in neurodegenerative disease research.
Prion diseases represent a unique category of neurodegenerative disorders caused by the misfolding of the cellular prion protein (PrP<sup>C</sup>) into the pathogenic scrapie isoform (PrP<sup>Sc</sup>). This misfolded protein exhibits remarkable templating properties, able to convert normal prion proteins into the disease-causing form through a seeded polymerization mechanism[@prusiner2024].
The pathological cascade in prion diseases includes:
Prionab pursues multiple therapeutic modalities to address prion diseases:
| Program | Approach | Indication | Development Stage |
|---------|----------|------------|-------------------|
| PRN-001 | Anti-prion antibody | Creutzfeldt-Jakob Disease (CJD) | Preclinical |
| PRN-002 | Small molecule | Creutzfeldt-Jakob Disease | Discovery |
| PRN-003 | Gene therapy approach | Fatal Familial Insomnia | Research |
| PRN-004 | Combination therapy | Prion disease prevention | Early research |
PRN-001 represents Prionab's lead therapeutic candidate, a monoclonal antibody designed to bind specifically to the pathological PrP<sup>Sc</sup> isoform while sparing the normal cellular prion protein. This selectivity is crucial, as the normal prion protein serves important physiological functions in neuronal maintenance and synaptic plasticity.
The antibody is designed to:
The PRN-002 program focuses on identifying small molecules that can stabilize the native conformation of the prion protein or prevent the structural transition to PrP<sup>Sc</sup>. This approach offers potential advantages including oral bioavailability and better distribution throughout the body.
Prionab's gene therapy program explores AAV-delivered approaches to modify prion protein expression in the central nervous system. While still in early research stages, this modality could provide long-lasting therapeutic benefit through single administration.
Prionab's pipeline addresses several fatal human prion diseases:
Creutzfeldt-Jakob Disease (CJD)
Prionab's research has implications for more common neurodegenerative diseases sharing protein misfolding pathology:
Prionab maintains active collaborations with:
The field of prion disease therapeutics has seen increased activity in recent years, with growing recognition of the need for disease-modifying treatments. Prionab continues to advance its pipeline through:
The following diagram shows the key molecular relationships involving Prionab discovered through SciDEX knowledge graph analysis: